Lucas de Breed, PhD MBA
Lucas de Breed, PhD MBA is the Founder and Managing Director of August Co (AUGC), offering outcomes-based financial solutions for the commercialization of advanced therapies, with a mission to enable broad access to patients.
Lucas has over a decade of international experience in all phases of drug development and commercialization, combined with a background in finance and investment. Previously as a Manager at Deallus, a global strategy consulting firm for Top 30 Pharma clients, he was responsible for the oncology business unit and founded the firm’s East Coast office. Consequently, as a Managing Director at Akero Health, he advised half a dozen early-stage therapeutics, medtech and diagnostics companies in both New York and the Bay Area. As an Investment Director at INKEF Capital, a leading Europeanhealthcare and technology venture capital firm, he committed approximately $120 million to US and European therapeutics start-ups in the therapeutic areas of oncology, audiology, fibrosis, neuromuscular disorders, metabolic diseases and monogeneic diseases, and served on the respective Boards.While at INKEF Capital, he was instrumental in setting the investment strategy, building out the investment team, and driving the AUM expansion to $600 million.
Lucas holds a PhD from University College London and an MBA from Stanford University. He has co-authored several scientific papers. He serves on the Scientific Advisory Board of Phosplatin Therapeutics, a clinical-stage oncology company, and on the Board of Directors of QuantumLeap Healthcare Collaborative, a 501C(3) charitable organization integrating high-impact clinical research with patient care to improve and save lives.